. Using NMR spectroscopy and X-ray crystallography, we identify the myristoyl pocket located near the carboxy terminus of the Abl kinase domain as the precise binding site of GNF-2 to Bcr-Abl. By selecting for Bcr-Abl alleles resistant to GNF-2 in vitro, we identify residues both within and outside of the myristate cleft that are required for drug efficacy. Simultaneous binding to Bcr-Abl of a myristoyl mimic and an ATP-competitive inhibitor decreases the appearance of resistance-conferring mutations and results in the inhibition of both wild-type and T315I Bcr-Abl kinase activity and cell growth. Hydrogen-exchange mass spectrometry demonstrates that binding of GNF-5 to the myristate pocket results in alterations to the conformational dynamics of the ATP-binding site and provides a possible mechanism for allosteric communication between these sites.
GNF-2 binds to the C-terminal myristate pocket of Abl GNF-2 had previously been suggested to bind in the myristate-binding pocket of Abl, on the basis of the observation that engineered mutations located at the entrance (A337N) and rear (A344L) of the myristoyl cleft conferred resistance to GNF-2 but not to imatinib 7 . To establish the GNF-2-binding site by an independent biophysical method, we used solution NMR 8, 9 on the Abl/imatinib/GNF-2 complex 10, 11 , to demonstrate that GNF-2 induces chemical shift changes that cluster around the myristate-binding pocket (Fig. 1a) . No significant perturbations in chemical shift were observed for the ATP pocket, indicating that GNF-2 does not interfere with imatinib for binding at the ATP-binding site. Myristic acid was found to induce qualitatively the same pattern of perturbations in chemical shift (Fig. 1b) , providing additional evidence that GNF-2 and myristate share the same binding site. Crystal structure of Abl/imatinib/GNF-2 complex. The binding of GNF-2 to the myristoyl pocket of Abl was further confirmed by X-ray crystallography. The structure of the Abl/imatinib/GNF-2 complex was obtained by soaking crystals of Abl/imatinib/myristate, obtained as described in ref. 10 , in an excess of GNF-2. As judged by the shape of the electron density ( Supplementary Fig. 1 ), GNF-2 replaces the myristoylated peptide in the crystals. There are two molecules in the asymmetric unit, and the myristate-binding site is fully occupied by GNF-2 in one and partly in the other. GNF-2 binds in an extended conformation in the myristate pocket with the CF 3 group buried at the same depth as the final two carbons of the myristate ligand (Fig. 2 ). There is a favourable, but probably weak, polar interaction between one fluorine atom and the main chain of L340 (similar to that observed between nilotinib and D381 of Abl) 12 , and there are watermediated hydrogen bonds, but no direct hydrogen bonds with the protein. As expected, most of the interactions between GNF-2 and the protein are hydrophobic. As discussed below, mutation of three residues near the mouth of the myristate-binding site (C464Y, P465S and V506L) is found to cause resistance to the binding of GNF-2, presumably for steric reasons. The overall structure of the Abl kinase domain complexed to GNF-2 is similar to that of the myristate complex (Fig. 2b) , with some small differences that probably result from crystal contacts, but no changes in the ATP-binding site.
GNF-2 analogue structure-activity relations
After the identification of GNF-2 as a lead compound, a systematic evaluation of the structural features necessary to impart function as a cellular Bcr-Abl inhibitor were investigated through the synthesis of more than 200 analogues and rationalized in the context of binding to the myristate-binding site (X.D. and N.S.G., unpublished observations, and Supplementary Fig. 2a ). The structure-activity relations are fully consistent with the conformation of GNF-2 observed in the crystal structure: the trifluoromethoxy group of GNF-2 can only be accommodated at the para position; the aniline NH is required because of the formation of a water-mediated hydrogen bond to the backbone carbonyls of A433 and E462; water-mediated hydrogen bonds between the carboxamide of GNF-2 and Abl confer enhanced inhibitory activity; and the extended compound conformation is required to fit the cylindrical binding cavity.
Drug combinations reduce emergence of resistant mutants
We sought to investigate the frequency with which Bcr-Abl-dependent Ba/F3 cells would become resistant to combinations of GNF-2 and imatinib in comparison with each compound alone. The number of resistant clones that emerged as a result of continuous exposure to 1 mM imatinib was decreased by at least 90% when cells were treated for up to 21 days with 1 mM imatinib combined with 5 or 10 mM GNF-2 (Fig. 3a) . These results demonstrate that combinations of GNF-2 and imatinib can cooperate to suppress the emergence of resistance mutations. Identification of the Bcr-Abl mutants resistant to GNF-2. To discover the full complement of Bcr-Abl mutants that induce resistance to GNF-2 we performed two types of selection. In the first, Bcr-Abltransformed Ba/F3 cells were cultured in the presence of increasing concentrations of GNF-2 to allow cells to evolve drug resistance as described previously for the ATP-competitive inhibitor PD166326 (ref. 13 ). In the second approach, Bcr-Abl was randomly mutated in Escherichia coli and the mutant clones were expressed in Ba/F3 cells, which were then grown in the presence of inhibitor 14 . These screens resulted in the identification of a total of 306 mutants, 163 (12 sites) from the first and 143 (22 sites) from the second (Supplementary Fig. 3 ). More than 80% of the resistant colonies contained Bcr-Abl mutations clustered in the myristate-binding pocket or the SH2 and SH3 domains ( Supplementary Fig. 3 ). This is in contrast to ATP-competitive inhibitors such as imatinib, PD166321 and AP23464 (refs 13-15) , for which most resistance mutations cluster adjacent to the kinase catalytic site.
To validate the functional relevance of these mutations, we engineered individual mutant Bcr-Abl-transformed Ba/F3 cells for nine of the most frequently isolated GNF-2-resistant mutations and for the T315I 'gatekeeper' mutation. These selected mutations located in the SH3 domain (P112S), the SH3-SH2 domain linker (Y128D), the SH2 domain (Y139C), the SH2-kinase-domain linker (S229P), the ATP-binding site (T315I) and adjacent to the myristate-binding site (C464Y, P465S, F497L, E505K and Y506L) were introduced individually into Bcr-Abl by site-directed mutagenesis. Of these, only the T315I substitution has previously been reported to confer resistance to imatinib 16, 17 . GNF-2 had an IC 50 against all ten mutants that was elevated 5-50-fold relative to that against wild-type Bcr-Abl-transformed Ba/F3 cells (Fig. 3b) . The three most frequently recovered mutations (60% of the total) were located in close proximity to the myristate-binding site (C464Y, P465S and E505K) and were shown to confer complete resistance to GNF-2 up to a concentration of 10 mM (Fig. 3c) .
To examine how the mutations affected the ability of GNF-2 to inhibit Bcr-Abl-mediated signalling, we examined Bcr-Abl autophosphorylation and phosphorylation of a downstream substrate, STAT5, after treatment with inhibitor ( Supplementary Fig. 4a ). At a concentration of 10 mM, GNF-2 could inhibit the phosphorylation of Bcr-Abl and STAT5 in all mutants except the three myristate-site mutations (E505K, P465S and C646Y) and the 'gatekeeper' T315I mutation. Mutations in the myristate pocket interfere with GNF-2 binding. We tested the ability of mutant Bcr-Abl proteins, obtained from crude cell lysates, to bind to a GNF-2 affinity resin ( Supplementary  Fig. 4b , c) 7 . These experiments revealed that only the mutations located in the myristate-binding site (C464Y, P465S and E505K) ablated the binding of Bcr-Abl to GNF-2; all other mutations retained binding to GNF-2. Using an NMR-based titration, we confirmed that GNF-2 still binds to the 'gatekeeper' mutant, T315I Abl (residues 229-500, not including helix I), albeit with half the affinity of the wild type ( Supplementary Fig. 5 ). These results suggest that the myristate-site mutations directly interfere with drug binding, whereas the non-myristate-site mutants function through a different mechanism, which may involve disfavouring the inhibited conformation induced after binding of GNF-2.
GNF-5 and nilotinib combinations inhibit T315I Bcr-Abl GNF-5, the N-hydroxyethyl carboxamide analogue of GNF-2 possessing similar cellular Bcr-Abl inhibitory activity but having more favourable pharmacokinetic properties, was chosen for further single and combination studies in vitro and in vivo ( Supplementary Fig. 2b ). Combinations of GNF-5 and nilotinib inhibited T315I Bcr-Abldependent cell growth with a calculated combination index 18 of 0.6, indicating moderate synergy (Fig. 4a ). For example, at a fixed GNF-5 concentration of 2 mM, nilotinib inhibits T315I Bcr-Abl-dependent proliferation with an IC 50 of 0.8 6 0.05 mM (mean 6 s.d.). Flow cytometry analysis showed that GNF-5 and nilotinib act additively to inhibit STAT5 phosphorylation; this could be rescued by the addition of interleukin-3 to the medium (Supplementary Fig. 6a ). Nilotinib and GNF-5 also exhibited cooperativity for inhibition of wild-type Bcr-Abl-transformed Ba/F3 cells with a calculated combination index of 0.6 ( Supplementary Fig. 6b ). We confirmed that the cooperativity observed between GNF-5 and nilotinib is directly mediated by the inhibition of Bcr-Abl, on the basis of the ability of a double mutation of T315I in the ATP-binding site and E505K in the myristate-binding site to confer complete resistance to the combination of both inhibitors in phosphorylation (Fig. 4b) and proliferation ( Supplementary  Fig. 6c, d ) assays. GNF-5 and nilotinib also acted cooperatively against p190 Bcr-Abl, a variant commonly found in acute lymphocytic leukaemia that typically responds only transiently to imatinib therapy 19 , with a calculated combination index of 0.5 ( Supplementary Fig. 7 ). Biochemical characterization of GNF-5 in combination with imatinib and nilotinib. To determine whether the additive interaction between GNF-5 and the ATP-competitive inhibitors imatinib and nilotinib observed in cellular assays could be confirmed at the protein level, we performed steady-state kinetic analyses of Abl kinase by using a pyruvate kinase-lactate dehydrogenase detection system 20 .
We first tested the inhibitory activity of imatinib, nilotinib and GNF-5 in bacterially expressed wild-type, T315I and E505K Abl kinases ( Supplementary Fig. 8 ). Inhibition of wild-type Abl was observed for all three inhibitors with GNF-5 showing an IC 50 of 0.22 6 0.01 mM, imatinib an IC 50 of 0.24 6 0.03 mM and nilotinib an IC 50 of 0.29 6 0.06 mM at an ATP concentration of 20 mM, which is close to the apparent K m under our assay conditions. Although the activity of recombinant Abl was previously reported to be insensitive to GNF-2 (ref. 7) , we subsequently discovered that this was due to the presence of Brij-35, a common additive to kinase assay buffers, which masked inhibition by GNF-2 (ref. 21) . The myristate-binding-site mutant E505K was inhibited by imatinib with an IC 50 of 0.22 6 0.03 mM and nilotinib with an IC 50 of 0.20 6 0.01 mM, but not by GNF-5 (IC 50 . 10 mM). The T315I mutant was not inhibited by imatinib or GNF-5, but nilotinib did exhibit weak activity against this mutant with an IC 50 of 1.42 6 0.3 mM. GNF-5 was confirmed to inhibit wild-type Abl in a non-ATP competitive fashion (Supplementary Fig. 9 ).
We next examined whether combinations of GNF-5 and nilotinib resulted in additive inhibition of wild-type, T315I or E505K recombinant Abl proteins. Positive cooperativity was observed for combinations of GNF-5 and nilotinib on the wild-type and T315I enzymes with calculated combination indices of 0.53 and 0.61, respectively (Fig. 4c,  d and Supplementary Fig. 10 ). For example, at a fixed GNF-5 concentration of 1 mM and an ATP concentration of 20 mM, the IC 50 values of nilotinib against T315I and wild-type enzyme were decreased 4.7-and 
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9.6-fold, respectively, compared with those calculated in the absence of GNF-5. As expected, no additivity was observed with the E505K myristate-binding-site mutant. These results demonstrate that allosteric communicationbetweenthemyristate-bindingsiteandtheATP-binding site can be observed in biochemical kinase assays. GNF-5 binding alters the conformation of the ATP-binding site. To examine how the binding of GNF-5 to the myristate-binding site might influence the conformational dynamics of the ATP-binding site and other regions of Abl, we performed hydrogen-exchange mass spectrometry. This technique allows the dynamics of a protein to be investigated by measuring the exchange of backbone amide hydrogens with the bulk solvent 22 . Unbound Abl and the GNF-5-Abl complex were independently exposed to D 2 O for periods ranging from 10 s to 4 h, as described previously 23 . Changes in deuterium incorporation in the presence of GNF-5 were observed in several peptides (Fig. 5) surrounding the myristate-binding cleft. In addition, changes in peptides near the ATP-binding site (for example residues 306-316 and 317-324) were also seen, implying that binding of GNF-5 affected the ATP-binding site. Hydrogen exchange in these peptides was not altered in a control experiment with GNF-5 and the non-binding Abl E505K myristate mutant, indicating that the binding of GNF-5 is what is responsible for the altered conformation and hydrogen exchange in the peptides near the ATP-binding site. These results demonstrate that ligation of the myristate-binding site can cause dynamic perturbations to residues in the ATP-binding site and provides a mechanism by which synergistic interactions between these two sites could occur.
Drug combinations inhibit T315I Bcr-Abl in vivo
The murine pharmacokinetic parameters of GNF-5 were measured and determined to be suitable for use of the compound in vivo (Supplementary Fig. 11 ). GNF-5 was shown to be efficacious in vivo at well tolerated doses in a murine xenograft model of p210 Bcr-Abl Ba/F3-induced leukaemia, but relapses were observed (Fig. 6a and Supplementary Fig. 12 ). The target modulation in vivo was further confirmed by examining the phosphorylation of STAT5 (Supplementary Fig. 13 ). GNF-5 and nilotinib combinations against T315I Bcr-Abl. To evaluate the in vivo efficacy of GNF-5 on wild-type and T315I BcrAbl further, we used a bone-marrow transduction/transplantation mouse model that more closely resembles human CML disease 24 . Initial experiments with p210 Bcr-Abl demonstrated that 50 mg kg 21 GNF-5 twice daily could normalize blood counts and spleen size (Supplementary Fig. 14) . We then addressed whether the combination of GNF-5 with nilotinib would result in efficacy in a T315I BcrAbl bone-marrow transduction/transplantation model. Mice treated twice daily with either nilotinib (50 mg kg 21 ) or GNF-5 (75 mg kg 21 ) alone at 15 days after transplantation showed no significant response compared with the vehicle group, with twofold to threefold higher cell counts and spleens fourfold larger than those of healthy mice. In contrast, the combination brought about a normalization of blood cell counts and spleen size without signs of toxicity, suggesting an additive effect of the compounds in a combination treatment (Fig. 6b, c) . To establish a correlation between efficacy and pharmacodynamic response, bone marrow cells from the different mouse groups were isolated at the end of the efficacy study, stained with anti-p-STAT5 and antiluciferase specific antibodies, and analysed by flow cytometry. The percentages of p-STAT5-positive Bcr-Abl-expressing bone marrow cells were similar (approximately 25%) in the groups treated with vehicle, with GNF-5 and with nilotinib. In the combination group, the proportion of p-STAT5-positive cells was about 6%, reflecting a correlation between the tumour growth inhibition and a block in Bcr-Abl signalling (Fig. 6d) . To determine the extent of the inhibition, mice transplanted with T315I Bcr-Abl-expressing bone marrow cells were treated with a single dose of the combination (50 mg kg 21 nilotinib plus 75 mg kg 21 GNF-5) or vehicle on day 21 after transplantation, and the bone marrow cells were collected and analysed at 3, 7, 16 and 24 h after dose. In the vehicle group, about 80% of the luciferase-positive cells had phosphorylated STAT5. At 3 h after dosing, STAT5 phosphorylation was decreased from 80% to 25%; from 7-24 h the number of p-STAT5-positive cells remained below 10%, showing a strong and sustained inhibition of BcrAbl-mediated signalling after administration of the GNF-5/nilotinib combination (Fig. 6e) .
In a third experiment we monitored the survival of the mice transplanted with T315I Bcr-Abl-transduced bone marrow and treated with GNF-5, nilotinib, or both in combination. Mice transplanted with T315I Bcr-Abl-transduced bone marrow and treated with vehicle control died by day 24 after transplantation, with a median survival of 22 days (Fig. 6f) . GNF-5 (75 mg kg 21 twice daily) extended survival (median 28 days) significantly compared with vehicle-treated controls (P 5 0.023). Mice treated with nilotinib alone (50 mg kg 21 twice daily) also survived longer (median 32 days) than those treated with vehicle (P 5 0.023). The overall survival of mice treated with GNF-5 plus nilotinib was improved compared with those treated with either GNF-5 alone (P 5 0.002) or nilotinib alone (P 5 0.002). All of these mice survived to day 50 after transplantation, after which the treatment was discontinued; 46 days after the combination treatment was completed, four out of five mice were surviving without signs of disease. Cumulatively, these results suggest that a combination of an ATP-competitive inhibitor with an allosteric inhibitor may be a therapeutically appropriate strategy for targeting the T315I Bcr-Abl mutation.
Discussion
The successful development of efficacious inhibitors against kinases such as Bcr-Abl, c-Kit and epidermal growth factor receptor (EGFR), which are activated by genetic alterations, has stimulated a massive effort to develop new ATP-competitive inhibitors targeted to a variety of kinases 25, 26 . One major problem for all clinically approved ATP-competitive kinase inhibitors is resistance that results from the selection of drug-resistant mutant forms of the kinase target. One One strategy for overcoming resistance mutations is to design new ATP-competitive inhibitors that derive potency and selectivity from alternative binding modes; this has been clinically validated by the development of dasatinib and nilotinib, which target most Bcr-Abl mutations except T315I. An alternative strategy is to find non-ATP competitive inhibitors that can regulate kinase activity allosterically. Allosteric inhibitors have been developed for multiple kinases including mTor 30 35 . GNF-2 and its analogues represent a new kind of non-ATP competitive Abl kinase inhibitor. The NMR, X-ray crystallography, mutagenesis and hydrogen-exchange experiments are all consistent with binding of GNF-2/5 to the myristate-binding site located near the C terminus of the kinase domain. On the basis of our accumulated data, we propose the following model for the inhibition mechanism of GNF-2 class compounds. Binding of GNF-2/5 to the myristate-binding site seems to induce a bent conformation of the aI helix that facilitates the stabilization of an inhibited conformation. As supported by the mutagenesis studies and kinase assays, functional inhibition by GNF-2/5 requires the involvement of the SH3 and SH2 domains. The hydrogen-exchange mass spectrometry data demonstrate that binding of GNF-5 to the myristate-binding site results in dynamic or conformational changes at the ATP-binding site. This suggests that binding of GNF-2/5 to the myristate-binding site causes structural reorganization, possibly communicated by means of a conformational rearrangement of other parts of Abl, which disrupts the catalytic machinery located in the ATP-binding site. Because we currently do not have a crystal structure with a construct that contains the SH3-SH2-kinase domain of Abl bound to GNF-2, we cannot draw firm conclusions about the precise conformation of the kinase induced by GNF-2/5.
We show that GNF-2/5 can act cooperatively with an ATP competitive inhibitor to inhibit both wild-type and T315I Bcr-Abl in biochemical and cellular assays, which is consistent with crystallographic and differential scanning calorimetry results (Supplementary Fig. 15 ). However, one puzzling question was why GNF-2/5 lacks significant biochemical and cellular potency against the T315I 'gatekeeper' Abl mutation. T315I Abl biochemical kinase activity can be decreased by 20% at GNF-5 concentrations below 0.5 mM, but further increases in GNF-5 concentration up to 10 mM do not result in superior inhibition (Fig. 4c) . Mutation of the 'gatekeeper' residue does not interfere substantially with the ability of GNF-2/5 to bind to Abl as determined by NMR and affinity chromatography, but it seems to disfavour the GNF-2/5-induced inhibited conformation. The hydrogen-exchange mass spectrometry data show that binding of GNF-5 results in decreased exchange in a peptide that contains the 'gatekeeper' residue. While we have not proved that this exchange phenomenon is functionally relevant to the inhibitory mechanism of GNF-2/5, it does suggest that the conformation and/or dynamics of the 'gatekeeper'-containing segment may be coupled with the ability of GNF-2/5 to inhibit Abl 36 . Although non-ATP competitive inhibitors will also be subject to inhibitor resistance through point mutation, we have shown that the combined application of ATP and non-ATP competitive inhibitors decreases the number of resistant clones that emerge as a response to continued exposure to a single agent. Furthermore we have shown that combined treatment of GNF-5 with nilotinib led to in vivo efficacy, resulting in complete disease remissions in a T315I BcrAbl mutant murine bone-marrow transplantation model. These findings should encourage the search for non-ATP competitive inhibitors that can selectively target the large number of kinases that become deregulated in cancer and other diseases. 
